Seagen announces multiple adcetris® (brentuximab vedotin) presentations at the upcoming ash annual meeting

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today announced multiple adcetris® (brentuximab vedotin) data presentations at the upcoming 62nd american society of hematology (ash) annual meeting and exposition, taking place virtually december 5-8, 2020. data presentations will include five-year updates from the phase 3 echelon-1 and echelon-2 clinical trials evaluating adcetris plus a chemotherapy combination regimen in frontline advanced stage hodgkin lymphoma (hl) or frontline pe
SGEN Ratings Summary
SGEN Quant Ranking